Skip to content
OpenCapital
Get started

CONMED CNMD EBITDA margin

EBITDA margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
34.4%+2.7pp
Stryker logo
StrykerSYK
24.6%+4.7pp
Boston Scientific logo
Boston ScientificBSX
25.2%+1.6pp
Vericel logo
VericelVCEL
9.6%+7.9pp
OSI Systems logo
OSI SystemsOSIS
14.3%-0.6pp
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
27.2%-3.0pp

Other financials

Income statement

See full
Revenue$317.0M-1.3%
Gross profit$183.4M+3.2%
Operating income$25.4M+59.3%
Net income$13.8M+129%
EPS (diluted)$0.45+137%

Balance sheet

See full
Cash & equivalents$35.0M-1.3%
Total debt$862.6M-3.6%
Total equity$1.0B+4.1%
Total assets$2.3B+0.8%

Cash flow

See full
Operating cash flow$13.5M-67.6%
CapEx$2.9M-23.5%
Free cash flow$10.6M-72.0%

Valuation

See full
Market cap$1.04B-35.6%
Enterprise value$1.87B-24.5%
P/E19×+5.4×
P/S0.8×-0.5×

Profitability

See full
Gross margin55.2%-1.0pp
Operating margin8.2%-5.6pp
Net margin4%-5.0pp
FCF margin9%-3.5pp

Returns & leverage

See full
Return on equity5.5%-7.5pp
Debt / equity0.8×-0.1×
Current ratio2.3×0.0×

Where this comes from

Calculated from CONMED’s reported figures.

ebitda/total revenue=12%

Based on trailing twelve months.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CONMED's EBITDA margin?
CONMED (CNMD) reported EBITDA margin of 12% in Q1 2026.
How has CONMED's EBITDA margin changed year-over-year?
CONMED's EBITDA margin decreased by 32.2% year-over-year, from 17.7% to 12%.
What is the long-term trend for CONMED's EBITDA margin?
Over 5 years (2020 to 2025), CONMED's EBITDA margin has grown at a -0.2% compound annual growth rate (CAGR), from 11.4% to 11.3%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.